This grant is for the purpose of accelerating the discovery and development of safe and effective therapeutic interventions specifically targeting Opioid Use Disorder (OUD) in patients concurrently diagnosed with co-occurring mental disorders (COMD). The HEAL Initiative is offering this funding opportunity to support innovative research that directly addresses the pressing, unmet need for advanced treatments in this vulnerable population. Eligible therapeutic approaches encompass a wide spectrum, including novel medications, innovative medical devices, and cutting-edge digital therapeutics. The ultimate objective is to significantly enhance the arsenal of available, effective, and safe treatments, thereby improving the health and well-being of individuals managing the complex challenges of both OUD and concurrent mental health conditions.
Opportunity ID: 342791
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-DA-23-049 |
| Funding Opportunity Title: | HEAL Initiative: Therapeutics Development for Opioid Use Disorder in Patients with Co-occurring Mental Disorders (UG3/UH3 – Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.213 — Research and Training in Complementary and Integrative Health |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jul 28, 2022 |
| Last Updated Date: | Jul 28, 2022 |
| Original Closing Date for Applications: | Feb 02, 2023 |
| Current Closing Date for Applications: | Feb 02, 2023 |
| Archive Date: | Mar 10, 2023 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Special district governments Native American tribal organizations (other than Federally recognized tribal governments) Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments Independent school districts Public housing authorities/Indian housing authorities For profit organizations other than small businesses County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education City or township governments Native American tribal governments (Federally recognized) Private institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. See full announcement for additional details on eligibility. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | THE PURPOSE OF THIS FOA IS TO SUPPORT RESEARCH THAT ACCELERATES THE DISCOVERY AND DEVELOPMENT OF SAFE AND EFFECTIVE THERAPEUTICS FOR OUD IN PATIENTS WITH CO-OCCURRING COMD. THE THERAPEUTIC INTERVENTIONS MAY INCLUDE MEDICATIONS, DEVICES, OR DIGITAL THERAPEUTICS. THE GOAL IS TO SUPPORT RESEARCH THAT ADDRESSES THE URGENT NEED TO HAVE SAFE AND EFFECTIVE THERAPEUTICS FOR OUD IN PATIENTS WITH CO-OCCURRING COMD. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-049.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 342791 Full Announcement-RFA-DA-23-049 -> RFA-DA-23-049-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH OER Webmaster OERWebmaster03@od.nih.gov Email: OERWebmaster03@od.nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-G | Use for due dates on or before January 24, 2023 | PKG00276198 | Jan 02, 2023 | Jan 24, 2023 | View | |
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00278461 | Jan 02, 2023 | Feb 02, 2023 | View |
Package 1
Mandatory forms
342791 RR_SF424_5_0-5.0.pdf
342791 PHS398_CoverPageSupplement_5_0-5.0.pdf
342791 RR_OtherProjectInfo_1_4-1.4.pdf
342791 PerformanceSite_4_0-4.0.pdf
342791 RR_KeyPersonExpanded_4_0-4.0.pdf
342791 RR_Budget_3_0-3.0.pdf
342791 PHS398_ResearchPlan_4_0-4.0.pdf
342791 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
342791 RR_SubawardBudget30_3_0-3.0.pdf
342791 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
342791 RR_SF424_5_0-5.0.pdf
342791 PHS398_CoverPageSupplement_5_0-5.0.pdf
342791 RR_OtherProjectInfo_1_4-1.4.pdf
342791 PerformanceSite_4_0-4.0.pdf
342791 RR_KeyPersonExpanded_4_0-4.0.pdf
342791 RR_Budget_3_0-3.0.pdf
342791 PHS398_ResearchPlan_5_0-5.0.pdf
342791 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
342791 RR_SubawardBudget30_3_0-3.0.pdf
342791 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
